Evaluating the Efficacy of ERG-Targeted Therapy in Vivo for Prostate Tumors
Annual rept. 21 Mar 2014-20 Mar 2015
JOHNS HOPKINS UNIV BALTIMORE MD
Pagination or Media Count:
The proposal centers on developing the principal investigator PI into an independent prostate cancer physician scientist, using as a vehicle this DoD award with specific research aims to examine the ERG oncoprotein as a target for prostate cancer therapy by using novel transgenic mice. As many as 50 of prostate cancers possess a chromosomal translocation involving the ERG oncogene. I hypothesized that ERG can serve as an effective molecular therapeutic target for prostate tumors using novel prostate tumor mouse models. During this fourth year of support we have not been able to adhere to our Statement of Work-- for Task 2 or Task 3. We were successful at completing Task1, but characterization of ERG expression from our prostate mouse model did not demonstrate any detectable prostate specific ERG expression at the protein level. Data from another project using the ARR2PB-tTA line lead us to conclude that the level of expression was insufficient for in vivo experimentation. To remedy this issue, we re-started Task 1 last year with the new prostate specific TET driver mouse, Hoxb13-rtTA. We have spent this last year reinitiating our studies on the ability of ERG to collaborate with AKT1 with these new mice, Hoxb13-rtTAtetO-ERG. We are in the process of breeding more mice and processing samples for analysis. Concurrently during this award period and made possible by this DoD award, the PI has made significant strides in promoting his career as an independently funded prostate cancer physician-scientist with national recognition.
- Genetic Engineering and Molecular Biology
- Anatomy and Physiology
- Medicine and Medical Research